Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for vasculitic neuropathies.

Kenneth C Gorson1

  • 1Neuromuscular Service, Department of Neurology, St. Elizabeth's Medical Center, Tufts University School of Medicine, 736 Cambridge Street, Boston, MA 02135, USA. kengorson@comcast.net

Current Treatment Options in Neurology
|February 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

Corrigendum to 'Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20' [Journal of the Neurological Sciences, 486 (2026) 125918].

Journal of the neurological sciences·2026
Same author

Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20.

Journal of the neurological sciences·2026
Same author

Measurement properties of the Inflammatory Rasch-built Overall Disability Scale (I-RODS) in patients with Guillain-Barré syndrome.

Journal of neurology·2026
Same author

Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.

Clinical drug investigation·2023
Same author

CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome.

Neurology·2023
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Vasculitic neuropathy involves blood vessel inflammation and nerve damage. Early treatment with prednisone and cyclophosphamide may improve outcomes for systemic and nonsystemic vasculitic neuropathy.

Area of Science:

  • Neurology
  • Immunology
  • Rheumatology

Background:

  • Vasculitis is blood vessel inflammation causing nerve damage (neuropathy).
  • Peripheral neuropathy can be the only sign of vasculitis, termed nonsystemic vasculitic neuropathy (NSVN).
  • Treatment involves immunosuppression, posing potential side effects.

Purpose of the Study:

  • To review the diagnosis and treatment of vasculitic neuropathy.
  • To discuss the role of immunosuppressive agents, including cyclophosphamide and alternatives.
  • To explore the controversial classification of diabetic lumbosacral radiculoplexus neuropathy as vasculitic.

Main Methods:

  • Diagnosis relies on tissue biopsy, preferably nerve biopsy.
  • High-dose prednisone is the standard initial therapy.

Related Experiment Videos

  • Cyclophosphamide is often used for systemic vasculitis; its role in NSVN is debated but shows promise.

    • Main Results:

    • Systemic vasculitis requires 3-12 months of cyclophosphamide alongside prednisone for sustained remission.
    • Retrospective data suggest combined prednisone and cyclophosphamide improve outcomes in NSVN.
    • Alternative immunosuppressants exist for intolerance or contraindications, though efficacy is unproven.

    Conclusions:

    • Prompt diagnosis and appropriate immunosuppressive therapy are crucial for managing vasculitic neuropathy.
    • The combination of prednisone and cyclophosphamide appears beneficial for both systemic and NSVN.
    • Further research is needed to confirm the efficacy of alternative treatments and clarify the vasculitic nature of certain neuropathies.